Clinical Trial Update: Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension [NA]

View source ↗

Summary

This clinical trial update reports on ambrisentan for early low-risk pulmonary arterial hypertension, with the study currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

Sponsor: Nanjing First Hospital, Nanjing Medical University | Conditions: Pulmonary Arterial Hypertension (PAH) | NA | Status: NOT_YET_RECRUITING